Iambic Therapeutics Marks a Key Milestone in Advancing Cancer Treatment: IND Submission for IAM1363, a Selective, Brain-Penetrant HER2 Inhibitor

The Bio Report: A Company Betting Its Physics-Based AI Will Fuel a Quantum Leap in Drug Discovery

BIOS Builders #23 with Tom Miller

Iambic Therapeutics Announces Close of Oversubscribed $100 Million Series B Financing to Advance AI-Discovered Therapeutics into Clinical Development and Enters Collaboration with NVIDIA

Ascenta Investor Day: A Conversation with David M. Rubenstein and Tom Miller

Tom Miller Presents at the NVIDIA Spring GTC23 Event

Entos (Now Iambic) in Collaboration with Caltech and NVIDIA: Advances in geometric deep learning for computational chemistry in Proceedings of the National Academy of Science USA

Caltech Heritage Project: A profile on Tom Miller, CEO of Iambic

Tom Miller Presents at PBSS Symposium 2021